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PIK3CA is the most commonly altered oncogene in head and neck squamous cell carcinoma (HNS CC). We evaluated the 
impact of nonsteroidal anti-inflammatory drugs (NSA IDs) on survival in a PIK3CA-characterized cohort of 266 HNS CC 
patients and explored the mechanism in relevant preclinical models including patient-derived xenografts. Among subjects 
with PIK3CA mutations or amplification, regular NSA ID use (≥6 mo) conferred markedly prolonged disease-specific survival 
(DSS; hazard ratio 0.23, P = 0.0032, 95% CI 0.09–0.62) and overall survival (OS; hazard ratio 0.31, P = 0.0043, 95% CI 
0.14–0.69) compared with nonregular NSA ID users. For PIK3CA-altered HNS CC, predicted 5-yr DSS was 72% for NSA ID users 
and 25% for nonusers; predicted 5-yr OS was 78% for regular NSA ID users and 45% for nonregular users. PIK3CA mutation 
predicted sensitivity to NSA IDs in preclinical models in association with increased systemic PGE2 production. These findings 
uncover a biologically plausible rationale to implement NSA ID therapy in PIK3CA-altered HNS CC.
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Introduction
Head and neck squamous cell carcinoma (HNS CC) is a common 
epithelial malignancy worldwide with high morbidity and mor-
tality. Primary risk factors for HNS CC include tobacco, alcohol, 
and human papillomavirus (HPV) infection. Regular use of as-
pirin was found to be protective against HNS CC development 
in a large cohort study of patients participating in the National 
Cancer Institute’s Prostate, Lung, Colorectal, and Ovarian (PLCO) 
randomized screening trial, as well as in other studies (Gohagan 
et al., 2000; Jayaprakash et al., 2006; Ahmadi et al., 2010; Wilson 
et al., 2013). Additional investigations, however, have reported 
inconsistent findings regarding the potential survival benefit of 
nonsteroidal anti-inflammatory drugs (NSA IDs) in HNS CC (Rafei 
et al., 2017; Kim et al., 2018). Moreover, while the PLCO study 
provided important epidemiological data for a role for NSA IDs 
in HNS CC consistent with findings from colorectal cancer (CRC) 
and breast cancer (Baron et al., 2003; Holmes et al., 2010), can-
didate biomarkers of response and molecular mechanisms were 
not identified.
Activating mutations in PIK3CA, the gene encoding p110α, 
the catalytic subunit of phosphoinositide-(3)-kinase α (PI3Kα), 
are common in HNS CC, with 174 of 504 (35%) tumors harbor-
ing PIK3CA mutation or amplification (Cancer Genome Atlas 
Network, 2015). Signaling through the PI3K pathway induces 
phosphorylation/activation of AKT (protein kinase B) and pro-
duction of prostaglandin E2 (PGE2) via cyclooxygenase-2 (COX2) 
enzyme, a target of NSA IDs.
A correlation between regular NSA ID use and improved sur-
vival in patients harboring canonical PIK3CA mutations was first 
described in CRC, an adenocarcinoma, although the mechanism 
responsible for the therapeutic benefit of NSA IDs was not de-
termined (Liao et al., 2012; Domingo et al., 2013; Elwood et al., 
2016). Commonly observed alterations in the PIK3CA gene re-
sult from either PIK3CA mutation or gene amplification, which 
occur at nearly equal frequency in HNS CC. Herein, we tested the 
hypothesis that regular NSA ID use is associated with improved 
disease-specific survival (DSS) and overall survival (OS) in pa-
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tients with PIK3CA-mutated or -amplified HNS CC. We also in-
vestigated PGE2 secretion as a potential mediator of response to 
NSA ID therapy in PIK3CA-altered preclinical models, hypothe-
sizing a unifying mechanism across cancers.
Results
Clinical and pathological information for our 266-patient cohort 
was obtained under the auspices of a prospective HNS CC bio-
banking protocol approved by the Institutional Review Board at 
the University of Pittsburgh. A detailed description of the con-
struction of our cohort is provided in the Materials and methods 
section. To investigate the interaction between NSA ID use, alter-
ation of PIK3CA, and HNS CC survival, we determined the mu-
tational and amplification status of PIK3CA in these 266 HNS CC 
tumors and extracted NSA ID use from the electronic medical 
record (EMR). Patients were classified as regular NSA ID users 
if the EMR supported ≥6 mo of “regular use,” defined as ≥2 d/
wk (Chan et al., 2005); never users if the EMR documented no 
prescription or self-reported use; and intermittent users if nei-
ther definition was met. Table S1 details the baseline clinical and 
pathological characteristics of this cohort according to PIK3CA 
alteration status and NSA ID use, and Table S2 details the adjuvant 
chemoradiation therapies delivered. The majority (67%) of our 
cohort received adjuvant chemotherapy, radiotherapy, or both 
(CRT). CRT was equally distributed among patients with PIK3CA 
mutation/amplification (66% received CRT) and among chronic 
NSA ID users (69% received CRT). DSS and OS did not differ by 
the administration of CRT (log rank P = 0.3 and 0.5, respectively) 
suggesting that the administration of adjuvant chemoradiother-
apy neither affected outcome directly nor confounded the con-
clusion regarding the impact of PIK3CA mutation/amplification 
and chronic NSA ID use. 84% of the patient cohort reported a 
positive smoking history. Smoking history was tested and found 
to have no effect on DSS (P = 0.301) or OS (P = 0.289). 75 tumors 
(28%) harbored mutation and/or amplification of PIK3CA. 37 of 
266 (14%) contained only mutation, 29 of 266 (11%) had only am-
plification, and 9 of 266 (3%) harbored both mutation and am-
plification. In tumors that harbored a PIK3CA mutation, 33 of 
46 (72%) had single canonical mutations (at residues E542, E545, 
and H1047), 12 of 46 (26%) had single noncanonical mutations, 
and 1 of 46 (2%) harbored both a canonical and a noncanonical 
mutation (H1047R and D743N). Mutations at E545 in the heli-
cal domain were the most common (14 E545K mutations and 1 
E545G mutation), followed by mutations at H1047 in the kinase 
domain (10 H1047R mutations and 3 H1047L mutations) and E542 
in the helical domain (six E542K mutations). Other mutations 
included two R115L mutations and one each of R38C, N345K, 
G363A, E476Q, D743N, Y890C, C971R, R975S, D1017H, T1025N, 
and H1048R. Regular NSA ID use was identified in 33% (25 of 75) 
of patients with PIK3CA-altered tumors and 39% (74 of 191) of 
those with WT, unamplified PIK3CA, and was independent of 
PIK3CA status (chi-square, P = 0.48). We observed no associa-
tion between either regular NSA ID use or PIK3CA status and any 
clinical or pathological variable except age (regular NSA ID users 
were on average 4 yr older) and disease status (regular NSA ID 
users with mutant (MT) or amplified PIK3CA were more likely 
to present with recurrent disease; P = 0.27). The median DSS was 
not reached but was at least 6 yr. Median OS was 66 mo, with a 
median follow-up of 40 mo (range 3–106 mo) among survivors. 
Aspirin was a component of the NSA ID regimen in 93% of regular 
users, and 73% took aspirin exclusively; 75% of aspirin-exclusive 
users took daily, low-dose (81 mg) drug (details regarding specific 
NSA ID use in the cohort are provided in Table S3). Most regular 
users (86%) initiated NSA ID therapy after receiving their HNS CC 
diagnosis. There was no indication that the diagnosis of HNS CC 
informed the decision to take NSA IDs.
The final multivariate proportional hazard model for DSS was 
adjusted for cancer type (primary versus recurrence), pathologi-
cal N (nodal) stage, and HPV status. In addition, we evaluated the 
interaction between PIK3CA status and regular NSA ID use. DSS 
among patients with WT, unamplified PIK3CA was unaffected by 
regular NSA ID use (Fig. 1 A; P = 0.61). By contrast, regular NSA ID 
use was strongly associated with improved DSS for patients 
with MT and/or amplified PIK3CA (Fig. 1 B; P = 0.0032). Among 
patients with altered PIK3CA, regular NSA ID users had an ab-
solute 5-yr DSS advantage of 47% (72% in regular users versus 
25% for nonregular users; Fig. 1 B; hazard ratio [HR] 0.24; 95% 
confidence interval [CI] 0.09–0.62; P = 0.0032). However, in the 
context of unaltered PIK3CA, the disease-specific HR for regu-
lar versus nonregular NSA ID use was not significant (0.86; 95% 
CI 0.48–1.54; Table S4). It should also be noted that PIK3CA al-
teration in nonregular NSA ID users was associated with worse 
DSS (P = 0.047), consistent with the known oncogenic proper-
ties of PIK3CA.
For OS, the final multivariate proportional hazard model was 
adjusted for PIK3CA status, primary versus recurrence, patho-
logical N stage, HPV status, and age at surgery. In addition, in-
teraction between regular NSA ID use and PIK3CA mutation/
amplification status was evaluated. As with DSS, regular NSA ID 
users with unaltered PIK3CA had equivalent OS to that of non-
regular users (Fig. 1 C; P = 0.95). However, among patients with 
altered PIK3CA, regular NSA ID users had an absolute 5-yr OS 
advantage of 33% (78% in regular users versus 45% for nonregu-
lar users; Fig. 1 D; P = 0.0043). The overall HR for regular NSA ID 
users with PIK3CA mutation and/or amplification was 0.31 (95% 
CI 0.14–0.69), compared with 0.98 (95% CI 0.60–1.62) for regular 
users with unaltered PIK3CA (Table S5). Interaction between mu-
tation/amplification status and regular NSA ID use was considered 
significant for the models (Fig. 1) for both DSS (P = 0.025) and OS 
(P = 0.017). PIK3CA alteration was also associated with worse OS 
among subjects who were nonregular NSA ID users (P = 0.014). The 
present study is the first to demonstrate a significant advantage in 
both DSS and OS among HNS CC patients taking regular NSA IDs 
that is dependent on the presence of a somatic PIK3CA alteration.
HPV status is recognized as a significant prognostic, but not 
predictive, biomarker in HNS CC, as patients with HPV-positive 
disease have improved outcomes with any standard-of-care ther-
apy (Buckley et al., 2016). When the model for DSS (Fig. 1) was 
segregated by HPV status, PIK3CA status, and NSA ID use, we ob-
served that for nonregular NSA ID users, PIK3CA alteration was 
associated with worse survival probability irrespective of HPV 
status (Fig. S1). The diminished DSS probability predicted by 
PIK3CA alteration was qualitatively reversed for patients tak-
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ing regular NSA IDs, where PIK3CA alteration predicted signifi-
cantly improved survival probability in both HPV-positive and 
HPV-negative disease (Fig. S1). Among HPV-positive patients 
taking regular NSA IDs (n = 23), no disease-specific deaths were 
observed with median follow-up of 36 mo (range, 5–97). Kaplan–
Meier plots of unadjusted survival estimates also demonstrated 
the essential interaction between PIK3CA status and NSA ID use 
(data not shown). These findings identify PIK3CA alteration as a 
molecular predictive and prognostic biomarker relevant to both 
HPV-positive and HPV-negative HNS CC.
To test our findings using in vivo HNS CC models, mice har-
boring six distinct patient-derived xenografts (PDXs) endoge-
nously expressing either MT or WT PIK3CA were treated with 
saline or the NSA IDs sulindac, celecoxib, or aspirin followed by 
assessment of tumor growth (see Table S6 for PIK3CA mutation 
details). A mixed linear model was fit to the log-transformed 
tumor volume data. Sulindac, celecoxib, or aspirin treatment 
reduced the growth rates of MT PIK3CA tumors compared with 
vehicle-treated tumors (P < 0.0001; Fig. 2, A and B). In contrast, 
the growth rates of PIK3CA WT tumors treated with NSA IDs did 
not differ compared with vehicle-treated controls (Fig. 2, A and 
B). These data support the potential benefit of regular NSA ID use 
in HNS CC patients with PIK3CA MT tumors.
Because nearly all patients in our analysis initiated NSA ID 
treatment following curative therapy (85 of 99), and the spec-
imens interrogated for this study consisted solely of baseline 
tumor-derived DNA from formalin-fixed, paraffin-embedded 
material, it is not possible to assess the proposed mechanism in 
human samples from this cohort, or any human cohort that we 
know to exist. Furthermore, we are unable to assess circulating 
levels of PGE2 in these patients, since baseline and/or post-NSA ID 
samples are unavailable. Therefore, we sought to identify a plau-
sible biological mechanism underlying our finding of improved 
survival in regular NSA ID users with PIK3CA-altered tumors by 
investigating HNS CC preclinical models (Scheper et al., 2007; 
Katoumas et al., 2015). We first identified a panel of HNS CC cell 
lines that endogenously express either WT or MT PIK3CA. PIK3CA 
MT HNS CC cell lines secreted significantly higher basal levels of 
PGE2 than did WT cells, indicating activation of COX2 signaling 
(Fig.  3  A). Non–small cell lung cancer (NSC LC) cells with MT/
Amp PIK3CA also secreted more PGE2 than did WT NSC LC cells, 
indicating that PIK3CA may activate COX signaling across cancer 
types and histologies (Fig.  3  B). We next engineered a PIK3CA 
WT HNS CC cell line (PCI-52) to stably overexpress WT PIK3CA 
or a representative PIK3CA mutant (H1047R). Overexpression of 
MT PIK3CA resulted in phosphorylation of AKT and the down-
stream target PRAS40 (Fig. S2). Similar findings were observed 
in a validation cohort of 165 HNS CC tumors, in which mutation 
and/or amplification of PIK3CA was significantly associated with 
elevated phosphorylation of AKT at T308 (P = 0.036) and S473 (P 
= 0.01) relative to WT/unamplified tumors (Fig. S3). Notably, cells 
with endogenous PIK3CA mutations and cells engineered to over-
express MT PIK3CA expressed markedly elevated levels of COX2 
enzyme (Fig. S2) and secreted significantly higher levels of PGE2 
(Fig. 3, A–C). Induction of COX2 by MT PIK3CA was due, at least in 
part, to transcriptional activation (data not shown). The enhanced 
Figure 1. Treatment benefit of regular NSA ID 
exposure for DSS and OS. (A) Model-predicted 
DSS probability indicates no survival difference 
between regular users (Yes, blue) versus never or 
occasional users (N o, orange) for HNS CC patients 
with unaltered PIK3CA. (B) Patients harboring 
mutated or amplified PIK3CA exhibited a survival 
advantage with regular NSA ID use (Yes, blue). (C) 
Model-predicted OS probability indicates no sur-
vival difference between regular users (Yes, blue) 
versus never or occasional users (No, orange) 
for HNS CC patients with unaltered PIK3CA. (D) 
Patients harboring mutated or amplified PIK3CA 
exhibited a survival advantage with regular NSA ID 
use (Yes, blue). Dotted vertical reference lines 
indicate 5 yr of follow-up. P values are based on 
Z statistics for testing contrasts derived from 
the design matrix of the selected regression 
model and are adjusted for HPV status, type of 
cancer (primary versus recurrence), pathological 
N stage, and age at surgery (for OS only). Gray 
bands indicate 95% confidence intervals.
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PGE2 secretion observed in HNS CC cell lines with endogenous 
PIK3CA mutations was markedly attenuated by treatment with 
the NSA ID sulindac (Fig. 3 D; 79% reduction in MT versus 45% in 
WT cells, on average; P = 0.0046), as was also the case in NSC LC 
lines with endogenous PIK3CA mutation or amplification 
(Fig. 3 E; 46% reduction in MT/Amp versus 29% in WT, on aver-
age). These results were confirmed in our engineered, isogenic 
HNS CC model, where sulindac treatment led to significantly 
greater reduction in PGE2 secretion in cells overexpressing MT 
versus WT PIK3CA (Fig.  3  F; average 93% reduction in PCI-52 
exogenously expressing MT PIK3CA versus 72% in vector-trans-
fected PCI-52 cells; P = 0.041). Similar findings were observed fol-
lowing treatment of cells with indomethacin (Fig. S4). Absolute 
PGE2 levels are shown in Fig. S5.
We next tested cell proliferation as a phenotypic indicator 
of NSA ID efficacy in our panels of HNS CC (Fig. 3 G) and NSC LC 
Figure 2. HNS CC PDXs harboring PIK3CA mutation are sensitive to NSA ID treatment. PDXs were implanted into the flanks of NSG mice and allowed to 
grow until palpable (n = 4–10 tumors per group). (A) Mice were then treated with vehicle (saline) or sulindac (30 mg/kg by i.p. injection every other day). Three 
distinct PIK3CA-MT PDX models exhibit significant growth inhibition upon sulindac treatment relative to vehicle control. By contrast, three PIK3CA-WT PDX 
models do not exhibit sulindac sensitivity. In an analysis combining all PDXs, the interaction of day and treatment group was significant (linear P = 0.016; qua-
dratic P < 0.0001), consistent with differential growth rates. (B) One PIK3CA-MT PDX and one PIK3CA-WT PDX (MT3 and WT3, respectively) were inoculated 
into mice (n = 10 tumors per group) as above and treated five times per week by oral gavage with vehicle (0.5% methylcellulose, 0.025% Tween 20), celecoxib 
(40 mg/kg), or aspirin (100 mg/kg). Only the PIK3CA-MT PDX exhibits growth inhibition upon celecoxib or aspirin treatment relative to vehicle (interaction 
test: linear P < 0.0001; quadratic P < 0.0001). Data are presented as mean ± SEM.
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(Fig. 3 H) cells with endogenous WT or MT PIK3CA, and in our 
isogenic HNS CC cells (Fig. 3 I). Sulindac treatment led to signifi-
cantly reduced cell proliferation in PIK3CA MT cells relative to 
WT cells in each model tested. We again detected significant in-
teractions between sulindac treatment and PIK3CA status (P = 
0.0009 for endogenous HNS CC models, P = 0.036 for endogenous 
NSC LC models, and P = 0.041 for isogenic HNS CC models), indi-
cating differential sensitivity to sulindac in PIK3CA WT versus 
MT models with respect to inhibition of cell proliferation. Impor-
tantly, exogenous expression of MT PIK3CA in a second isogenic 
HNS CC cell line model (Cal27) confirmed significantly enhanced 
growth inhibition following sulindac treatment in cells express-
ing MT versus WT PIK3CA (P = 0.0029; data not shown). Similar 
levels of growth inhibition and reduction of PGE2 were seen in 
HNS CC cells with MT PIK3CA following treatment with either 
sulindac or celecoxib (not shown). Similarly, sulindac treatment 
enhanced induction of apoptosis in cells expressing MT ver-
sus WT PIK3CA (data not shown). Sulindac also significantly 
inhibited colony formation in soft agar in PIK3CA MT HNS CC 
cells compared with WT HNS CC models (data not shown), 
providing a plausible mechanism for the improved DSS in the 
human HNS CC cohort.
We further observed that mice harboring PDX tumors with 
MT PIK3CA exhibited elevated levels of circulating PGE2 com-
pared with mice with WT PDX tumors (Fig. 4 A). Moreover, treat-
ment of the PDX-bearing mice with celecoxib, a COX2-selective 
NSA ID, resulted in significantly lower circulating PGE2 in mice 
with MT PIK3CA tumors compared with those with WT tumors 
(Figs. 4 B). Similar results were observed with sulindac or aspirin 
treatment (Fig. S5). Taken together, our findings indicate that 
Figure 3. Cancer cell lines with PIK3CA alteration are more sensitive to NSA ID treatment. (A–C) Basal PGE2 secretion (measured via ELI SA) is higher in (A) 
HNS CC (P = 0.0052) cells harboring endogenous PIK3CA mutations (Cal33, Detroit562, and HSC-2) or (B) NSC LC (P = 0.017) cells harboring endogenous PIK3CA 
mutation or amplification (H460, PIK3CA MT; H3255, PIK3CA amplification) compared with cell lines containing WT, unamplified PIK3CA (Cal27, FaDu, and PE/
CA-PJ34.12 for HNS CC; H358 and H1437 for NSC LC), and in (C) isogenic HNS CC cells (PCI-52) engineered to overexpress MT PIK3CA (P = 0.0374). For HNS CC 
(A, D, and G), three distinct cell lines were used for each genotype, MT or WT; for NSC LC (B, E, and H), two MT/Amp cell lines and two WT cell lines were used. 
(D–F) Sulindac treatment (48 h) leads to greater reduction of PGE2 secretion in (D) HNS CC (P = 0.0046) but not (E) NSC LC cells harboring endogenous PIK3CA 
mutations/amplification (P = 0.24), and in (F) isogenic HNS CC cells overexpressing MT PIK3CA (P = 0.041). (G–I) Sulindac treatment (48 h) more potently inhibits 
cell proliferation in (G) HNS CC (P = 0.0009) or (H) NSC LC (P = 0.036) cells harboring endogenous PIK3CA mutations/amplification, and in (I) isogenic HNS CC 
cells overexpressing MT PIK3CA (P = 0.041). All panels are depicted as mean + SD (error bars). All experiments were performed in triplicate and repeated once. 
Data were analyzed by two-way analysis of variance with interaction in which cell type (mutated versus WT) was crossed with treatment (vehicle, sulindac). 
Specific hypotheses were evaluated by t test with pooled estimates of SE. *, P ≤ 0.05; **, P ≤ 0.005; ***, P ≤ 0.001. ns, not significant.
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PIK3CA mutation or amplification activates PI3K pathway signal-
ing in HNS CC tumors and preclinical models, likely resulting in 
elevated PGE2 secretion via activation of COX2 enzyme, leading 
to enhanced NSA ID sensitivity.
Discussion
Epidemiological studies to date in CRC have highlighted an in-
teraction between canonical PIK3CA mutation, aspirin use, and 
patient survival, where the underlying biological mechanism 
remains incompletely understood. Our experimental evidence 
is in line with the hypothesis that genomic alteration of PIK3CA 
up-regulates PGE2 secretion, which in turn stimulates cellular 
proliferation. This autocrine regulatory pathway results in dif-
ferential susceptibility to COX targeting by NSA IDs. While our 
results do not rule out molecular mechanisms in addition to PGE2 
secretion, they are consistent with an interaction between the 
PI3K and COX pathways in HNS CC, which may contribute to an 
oncogene addiction phenotype. In addition, the COX–PGE2 path-
way has been implicated as a major immune-inhibitory pathway 
in HNS CC (Mandapathil et al., 2010). The precise role of COX2 
in mediating the impact of NSA IDs on PIK3CA MT cancer across 
different tumor lineages remains incompletely understood. While 
an enhanced benefit of adjuvant aspirin was reported among pa-
tients with COX2-overexpressing CRC (Chan et al., 2009), a recent 
study found that the impact of aspirin in PIK3CA MT breast can-
cer preclinical models was COX2 independent (Henry et al., 2017). 
Unfortunately, current methodologies are unable to assess PGE2 
expression or secretion in formalin-fixed, paraffin-embedded 
specimens, limiting the analysis of our human specimens. Fur-
thermore, NSA ID use in this cohort generally followed curative 
intent treatment and therefore we are not able to determine if 
NSA ID use is associated with lower COX2 expression in the tumor.
It is noteworthy that the prior report in CRC only analyzed 
the interaction of the three canonical PIK3CA mutations (exons 9 
and 20) with NSA ID use and survival. In HNS CC, 64% of PIK3CA 
mutations are canonical, while 36% are noncanonical (Domingo 
et al., 2013). Our study sequenced all PIK3CA exons and as-
sessed the impact of both canonical and noncanonical PIK3CA 
mutations in addition to determining the contribution of gene 
amplification, thus implicating activation of PI3K signaling as 
the primary mechanism for NSA ID benefit. In addition, CRC is 
an adenocarcinoma that is distinct from HNS CC with respect to 
risk factors, prevalence, and known carcinogenic mechanisms. 
Therefore, our finding that NSA ID use in the context of PIK3CA 
mutation or amplification enhances DSS in both HPV-positive 
and HPV-negative HNS CC (which are also clearly distinct with 
respect to risk factors), as well as our results in PIK3CA MT 
NSC LC cells, suggests that adjuvant NSA ID administration may 
significantly improve outcome in many PIK3CA-altered cancers. 
The implication of our findings may provide a dramatic impact 
on human health.
The present study was conducted using a cohort of conve-
nience and, as such, has some inherent limitations. Regular use of 
NSA IDs was defined through interrogation of the EMR by a com-
bination of prescription refill records and patient self-reporting, 
which by themselves do not necessarily ensure an accurate es-
timation of actual use. Regular NSA ID users by definition had 
to survive at least 6 mo, which introduces a potential, although 
limited, bias. Limitations in cohort size, particularly among sub-
groups, coupled with inconsistencies in the type, timing, and 
dosages of NSA ID therapy taken by patients in this study limits 
our ability to make definitive statements regarding specific ther-
apeutic recommendations. To minimize the possibility of index 
event bias, we carefully adjusted for confounding variables such 
as disease stage and HPV status (Tables S3 and S4).
We conclude that regular NSA ID use likely confers a statisti-
cally and clinically significant advantage in DSS as well as OS in 
patients with PIK3CA-altered HNS CC, irrespective of HPV status, 
through direct interaction between the PI3K and COX pathways. 
The magnitude of this apparent advantage, especially given the 
marked morbidity and mortality of this disease, warrants further 
study in a prospective randomized clinical trial.
Materials and methods
Cohort construction
Clinical and pathological information was obtained under the 
auspices of a prospective HNS CC biobanking protocol approved 
by the Institutional Review Board of the University of Pittsburgh 
and curated by the HNS CC Specialized Program of Research Ex-
cellence (P50CA097190). Of 1,725 patients with surgically re-
sected HNS CC at the University of Pittsburgh Medical Center 
between May 2008 and March 2013, 807 provided written in-
formed consent for inclusion of their tumors on prospective tis-
sue microarrays. At the time of this study, 216 of these cases were 
Figure 4. PGE2 levels are elevated in PIK3CA MT HNS CC 
PDX models and are significantly reduced by celecoxib 
treatment. Mouse serum was extracted immediately after 
sacrifice following treatment with vehicle or celecoxib as 
described in Fig.  2. Serum PGE2 levels were measured in 
triplicate for each mouse using a PGE2 ELI SA kit per the 
manufacturer’s instructions and normalized to the tumor 
volume per mouse. (A) PGE2 levels in vehicle control treated 
mice. (B) Percent PGE2 levels in celecoxib-treated mice rela-
tive to vehicle control. Significantly lower serum PGE2 levels 
were observed in mice harboring PIK3CA-MT PDXs treated 
with celecoxib relative to PGE2 levels in vehicle-treated 
control mice harboring PIK3CA-WT PDXs. Each data point 
represents the mean of triplicate measurements for each 
mouse, while whiskers represent the overall mean ± SEM.
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available for targeted PIK3CA sequencing. An additional 141 cases 
previously characterized by whole-exome sequencing were iden-
tified (Stransky et al., 2011; Lui et al., 2013; Cancer Genome Atlas 
Network, 2015). These 357 cases were filtered according to the 
following inclusion criteria: determinate PIK3CA mutation and 
amplification testing; >2 mo of follow-up; surgery within 6 mo of 
diagnosis; and known cause of death. 91 cases were excluded for 
nonsquamous histology (10), indeterminate PIK3CA status (51), 
<2 mo of follow-up (4), delay between diagnosis and surgery (23), 
or unknown cause of death (3). In total, 266 cases were included 
for analysis. All patients were treated with curative-intent sur-
gery and standard adjuvant therapy, including radiation and che-
motherapy as indicated by clinicopathologic features.
Statistics and model generation
DSS and OS were defined as elapsed time from the date of re-
section until death due to cancer or death from any cause, re-
spectively. Patients alive at last date of follow-up were censored. 
Multivariate, proportional hazards regression models for DSS 
and OS were constructed. Covariates considered for association 
within each model included gender, age at surgery, year of sur-
gery, tumor site, tumor stage, nodal stage, HPV status, cancer type 
(primary or recurrent), PIK3CA status (dichotomized as altered 
by mutation/amplification versus WT), and NSA ID use (dichot-
omized as regular versus nonregular use). Two-way interactions 
among these variables were also evaluated. DSS and OS models 
were evaluated with the Akaike and Bayesian information criteria 
to balance fit and complexity. Final models for DSS and OS were 
found to meet proportional hazards assumptions using Schoen-
feld residuals (Grambsch and Therneau, 1994). Survivor functions 
were estimated from final proportional hazards models by the 
discrete hazard method of Kalbfleisch and Prentice (2011). Tests 
of differences between groups were based on forming contrasts 
derived from the design matrix of the selected regression model. 
Computations were made using the rms package (Harrell, 2015) 
for R (R Team, 2014) statistical software. In vitro data were ana-
lyzed by two-way analysis of variance with interaction in which 
cell type (mutated versus WT) was crossed with treatment (vehi-
cle, sulindac). Expression of PGE2 was natural log–transformed 
before analysis; survival percentage in proliferation experiments 
was untransformed. Specific hypotheses were evaluated by a t test 
with pooled estimates of standard error. Tumor volumes in PDX 
experiments were analyzed by longitudinal mixed effects linear 
models applied to log-transformed volume measurements.
Animals
Animal procedures were performed in accordance with proto-
cols approved by the Institutional Animal Care and Use Com-
mittee of the University of California, San Francisco. 5–6-wk old 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from 
the University of California, San Francisco Breeding Core Fa-
cility. PDXs were implanted into the flanks of NSG mice under 
anesthesia and allowed to grow until palpable (∼100 mm3). Mice 
were treated with vehicle control (saline) or sulindac sulfide i.p. 
(30 mg/kg; Sigma-Aldrich) every other day. For experiments in-
volving treatment with celecoxib, mice were treated with vehicle 
control (0.5% methylcellulose + 0.025% Tween 20) or celecoxib by 
oral gavage (40 mg/kg; Sigma-Aldrich) five times per week. For 
experiments involving treatment with aspirin, mice were treated 
with vehicle control (0.5% methylcellulose + 0.025% Tween 20) or 
aspirin by oral gavage (100 mg/kg; Sigma-Aldrich) five times per 
week (O’Connor et al., 2004; Scheper et al., 2007; Yip-Schneider 
et al., 2007; Tury et al., 2016). Tumors were measured every other 
day by Vernier caliper in two dimensions, and volume was cal-
culated as (larger measurement) × (smaller measurement)2/2. 
Mixed linear models were applied to log-transformed tumor vol-
umes. Specifically, we fit random coefficient models to verify the 
interaction between the four groups (formed by crossing muta-
tion status and NSA ID exposure) and day of tumor measurement.
Clinicopathologic data and biospecimen analysis
Clinicopathologic variables including age, sex, stage, histopatho-
logic features, and treatment were entered into the clinically an-
notated database of the University of Pittsburgh Head and Neck 
Cancer Specialized Program of Research Excellence (SPO RE) at 
the time of informed consent to the biobanking protocol. DSS and 
OS outcomes are updated monthly and cross-referenced to the 
Social Security Death Index and the Cancer Registry of the State 
of Pennsylvania at least annually. The database is linked to the 
University of Pittsburgh Medical Center EMR where prescription 
medications and self-reported over-the-counter medications are 
recorded by date. Use of aspirin and other NSA IDs was extracted 
from the EMR for each case, including dates of exposure and dose 
when available. Patients were classified as regular NSA ID users 
if the EMR supported ≥6 mo of regular use, where “regular use” 
was defined as ≥2 d/wk (Chan et al., 2005); never users if the 
EMR documented no prescription or self-reported use; and in-
termittent users if neither definition was met. PIK3CA mutation 
and amplification status for the whole-exome sequencing cases 
were generated as previously described (Stransky et al., 2011; Lui 
et al., 2013; Cancer Genome Atlas Network, 2015). For new cases, 
formalin-fixed, paraffin-embedded tumor cores, microdissected 
under guidance from hematoxylin/eosin-stained sections, were 
obtained for genomic DNA extraction, and next generation se-
quencing was performed for all PIK3CA exons. DNA extraction, 
sequencing, coverage analysis, and variant detection were per-
formed by Genewiz. Using a custom primer set, the Ion AmpliSeq 
Library Preparation Kit 2.0, Ion 316 chips, the Ion Personal Ge-
nome Machine, and the Torrent Suite program 4.0, VCF (variant 
call format) files for each sample were generated and aligned to 
the reference sequence hg19. Variants were considered valid and 
reported if they achieved a Phred-based quality score >100 (base 
call accuracy >99.99%). Fluorescence in situ hybridization was 
performed on tissue microarrays to assess PIK3CA copy number, 
where amplification was defined as PIK3CA: CEP3 > 2. HPV sta-
tus was assessed by p16 immunohistochemistry and HPV in situ 
hybridization (ISH) in 240 cases, using standard techniques. p16 
positivity was defined as strong, diffuse cytoplasmic, and nuclear 
p16 expression in >70% of tumor cells as previously described 
(Chiosea et al., 2013). Oropharynx cases positive for p16 and HPV 
ISH, or p16 only, were classified as HPV positive. Non-orophar-
ynx cases positive for both p16 and HPV ISH were also classified 
as HPV positive. The clinicopathologic database was constructed 
independently from the database of PIK3CA alterations.
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Cell lines and PDXs
A panel of HNS CC cells with or without endogenous PIK3CA mu-
tation was identified using the Cancer Cell Line Encyclopedia. All 
of the HNS CC cell lines that were used which harbor endogenous 
PIK3CA mutations harbor the canonical H1047R mutation. Cal27 
(RRID: CVCL_1107), FaDu (RRID: CVCL_1218), and Detroit 562 
(RRID: CVCL_1171) cells were obtained from the American Type 
Culture Collection. PE/CA-PJ34 (clone C12; RRID: CVCL_2679) cells 
were obtained from Sigma-Aldrich. Cal33 (RRID: CVCL_1108) 
were obtained from Gerard Milano at the Centre Antoine Lac-
assagne (Nice, France). HSC-2 (RRID: CVCL_1287) cells were 
obtained from the Health Science Research Resources Bank. The 
PCI-52 (RRID: CVCL_RJ99) cell line was obtained from Dr. Theresa 
Whiteside at the University of Pittsburgh (Pittsburgh, PA). Cal27, 
FaDu, Detroit 562, Cal33, HSC-2, and PCI-52 cells were maintained 
in DMEM (Corning) containing 10% FBS (Gemini Bio-Products) 
and penicillin/streptomycin (Life Technologies). PE/CA-PJ34 
cells were maintained in Iscove’s DMEM (Corning) containing 
10% FBS, 2 mM l-glutamine (Life Technologies), and penicillin/
streptomycin. Lung cancer cell lines were obtained from Ameri-
can Type Culture Collection and maintained in RPMI-1640 (Life 
Technologies) containing 10% FBS and penicillin/streptomycin. 
Cell line identities were verified by short tandem repeat profiling 
performed by Genetica DNA Laboratories or the DNA Sequencing 
Facility at the University of California, Berkeley, most recently 
on February 9, 2018. All cells were maintained in a humidified 
incubator at 37°C and 5% CO2 for ≤6 mo before retesting or starting 
new cultures from previously tested stocks stored in liquid nitro-
gen. Mycoplasma status was not routinely assessed. PDXs were 
developed from human HNS CC tumors as described previously.
Plasmids, lentiviral production, and stable cell line selection
pHAGE-PIK3CA WT and pHAGE-PIK3CA H1047R plasmids were 
a gift from Dr. Gordon Mills (MD Anderson Cancer Center, Hous-
ton, TX) and were cloned into the doxycycline-inducible pLVX-
Puro vector (Clontech) using the gateway cloning system (Life 
Technologies). All vectors were sequence validated. Lentivirus 
was produced according to the Lenti-X Tet-One Inducible Ex-
pression Systems Manual (Clontech) and subsequently used to 
establish PCI-52 stable cell lines after selection with puromycin 
(0.5 µg/ml) for several weeks. Validation of each stable clone was 
performed 48 h after incubation with doxycycline (1 µg/ml) and 
subsequently examined by immunoblot for Flag tag expression 
(Sigma-Aldrich).
PGE2 ELI SA
Secreted PGE2 was measured using the human PGE2 detection kit 
from Cayman Chemical Company according to the manufactur-
er’s instructions. For baseline measurements, cells were plated 
in triplicate at 10,000 cells per well (100,000 for engineered 
cells) in 24-well dishes. After 24  h, media were replaced with 
serum-free media followed by an additional 48-h incubation 
and subsequent PGE2 measurement. For treatment studies, cells 
were treated with 200 µM sulindac, 200 µM indomethacin, or 
100 µM celecoxib in serum-free media for 48 h followed by PGE2 
measurement. For inducible, engineered cell lines, 1 µM doxycy-
cline was added to the medium for 48 h before the experiment.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay
Cells were plated at 10,000 cells per well (100,000 for engineered 
cells) in 24-well plates 24 h before treatment with 200 µM sulin-
dac or indomethacin, or 100 µM celecoxib, for 48 h. MTT assays 
were performed by replacing media with 5 mg/ml MTT (Sig-
ma-Aldrich) in PBS followed by permeabilization and dissolution 
of formazan product in dimethyl sulfoxide. Absorbance at 570 
nm was detected with an Epoch plate reader (BioTek) and con-
sidered a surrogate for cell viability/survival.
Immunoblotting
Whole-cell lysates were harvested using radioimmunoprecipi-
tation assay lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
0.1% SDS, 0.5% deoxycholate, and 0.5% NP-40) supplemented 
with protease and phosphatase inhibitor cocktails. Samples 
were sonicated for 10  s and then centrifuged at 15,000  g for 
10 min at 4°C. Bradford assay was used to determine protein 
concentrations (Bio-Rad Laboratories). Equal amounts of pro-
tein were fractionated by SDS-PAGE, transferred to a poly-
vinylidene fluoride membrane (Bio-Rad Laboratories), and 
analyzed by incubation with the corresponding primary an-
tibodies from Cell Signaling Technology: p-AKT-S473 (4060), 
AKT (4685), p-PRAS40-T246 (13175), PRAS40 (2691), COX2 
(12282), and GAP DH (5174). Anti-Flag M2 (Sigma) was used to 
detect PI3K overexpression. β-Tubulin (Abcam) was used as an 
alternative loading control. Proteins were detected via incuba-
tion with HRP-conjugated secondary antibodies and enhanced 
chemiluminescence Western Blotting Substrate (Santa Cruz 
Biotechnology).
Online supplemental material
Fig. S1 illustrates the impact of NSA ID use on DSS according 
to HPV status. Fig. S2 shows activation of PI3K signaling and 
COX2 expression in HNS CC cells expressing MT PIK3CA. Fig. 
S3 demonstrates correlation of PIK3CA mutation or amplifica-
tion with increased PI3K signaling in an independent HNS CC 
patient cohort. Fig. S4 shows that cancer cells with altered 
PIK3CA are more sensitive to indomethacin treatment. Fig. S5 
shows that cancer cells or PDXs with altered PIK3CA demon-
strate a greater reduction of PGE2 secretion upon NSA ID treat-
ment. Table S1 lists the baseline characteristics of this cohort. 
Table S2 lists adjuvant therapies used in this cohort. Table 
S3 lists specific NSA IDs used in this cohort among 99 regular 
users. Table S4 lists HRs for DSS by PIK3CA status and regu-
lar NSA ID exposure. Table S5 lists HRs for OS by PIK3CA status 
and regular NSA ID exposure. Table S6 lists PIK3CA mutations 
in HNS CC PDX models.
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